Equities

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc

Actions
  • Price (USD)12.77
  • Today's Change-0.04 / -0.31%
  • Shares traded906.00
  • 1 Year change-52.70%
  • Beta0.5677
Data delayed at least 15 minutes, as of May 23 2024 14:31 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's direct-acting antiviral (DAA) combination treatment for HCV, which is marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Its research and development programs are in virology, namely RSV, SARS-CoV-2 and hepatitis B virus. The Company has a research program targeting development of single agents with broader spectrum antiviral activity against both RSV and human metapneumovirus (hMPV).

  • Revenue in USD (TTM)72.88m
  • Net income in USD-131.74m
  • Incorporated1995
  • Employees145.00
  • Location
    Enanta Pharmaceuticals Inc500 Arsenal StreetWATERTOWN 02472United StatesUSA
  • Phone+1 (617) 607-0800
  • Fax+1 (617) 607-0530
  • Websitehttps://www.enanta.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sanara Medtech Inc68.00m-4.89m261.17m107.00--6.03--3.84-0.5873-0.58738.155.021.041.998.63635,556.60-7.68-17.73-9.30-22.0788.8088.08-7.39-17.131.02-9.210.184--41.7761.9345.79--99.09--
XBiotech Inc0.00-30.74m261.63m92.00--1.25-----1.01-1.010.006.870.00----0.00-13.0831.88-13.6833.27------877.30----0.04560.00-100.00--25.36--24.30--
TriSalus Life Sciences Inc21.98m-68.07m262.90m112.00------11.96-2.09-2.090.7291-1.311.171.267.49196,276.80-339.18---11,196.50--86.74---291.08--0.714-16.82----49.31---26.51------
Emergent Biosolutions Inc1.19bn-565.30m263.06m1.60k--0.3962--0.2219-10.87-10.8722.8612.670.49881.996.09740,875.00-23.79-2.94-38.89-3.6641.1953.24-47.69-5.950.55380.06360.5771---6.106.05-259.40---4.29--
ASP Isotopes Inc1.27m-19.62m263.47m76.00--23.52--206.91-0.5335-0.53350.03440.21640.0425----16,755.00-65.49---81.59--32.81---1,542.66-----17.390.633-------229.34------
Rani Therapeutics Holdings Inc0.00-33.08m264.20m140.00--34.16-----1.29-1.290.000.15340.00----0.00-87.80---140.92-------------28.750.6695-------11.06------
Acrivon Therapeutics Inc0.00-64.12m264.62m58.00--1.80-----2.88-2.880.004.770.00----0.00-44.11---46.46--------------0.00-------93.76------
Medifast Inc897.81m67.76m268.29m634.003.961.273.310.29886.206.2082.1519.292.883.37--1,416,106.0021.7141.2532.6269.3873.1573.207.5510.062.25--0.0049.18-32.9416.43-30.7512.255.5917.72
Adaptimmune Therapeutics PLC - ADR18.36m-163.41m268.34m449.00--11.01--14.62-0.7285-0.72850.08340.09540.0672--3.6340,886.41-59.85-41.19-78.55-48.21-----890.13-714.26----0.00--122.050.259531.18--0.7202--
Metagenomi Inc44.76m-68.26m268.62m236.00------6.00-1.82-1.821.195.73------189,644.10-------------152.50------0.00--160.21---56.57------
Enanta Pharmaceuticals Inc72.88m-131.74m271.31m145.00--1.63--3.72-6.25-6.253.467.840.197--5.70502,627.60-35.60-14.56-40.33-15.62-----180.75-54.96----0.0085---8.07-17.45-9.91--24.89--
Century Therapeutics Inc1.37m-133.47m273.40m152.00--1.20--199.56-2.22-2.220.02272.740.0034----9,013.16-33.17---35.08-------9,742.41------0.00---57.01---4.38------
ESSA Pharma Inc0.00-27.73m275.05m50.00--2.06-----0.6282-0.62820.003.010.00----0.00-18.71-23.01-19.12-23.67------------0.00------24.27------
Caribou Biosciences Inc33.40m-115.26m280.89m158.00--0.8182--8.41-1.45-1.450.41363.800.0886--11.68211,417.70-30.56---33.02-------345.05------0.00--148.91---2.66------
Black Diamond Therapeutics Inc0.00-79.79m283.51m54.00--2.54-----1.70-1.700.001.990.00----0.00-57.38-40.29-64.24-43.29------------0.00------9.57---15.37--
Data as of May 23 2024. Currency figures normalised to Enanta Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

63.36%Per cent of shares held by top holders
HolderShares% Held
Farallon Capital Management LLCas of 31 Mar 20242.10m9.90%
Morgan Stanley & Co. LLCas of 31 Mar 20241.92m9.09%
The Vanguard Group, Inc.as of 31 Mar 20241.91m9.02%
BlackRock Fund Advisorsas of 31 Mar 20241.52m7.19%
Armistice Capital LLCas of 31 Mar 20241.24m5.84%
Krensavage Asset Management LLCas of 31 Mar 20241.12m5.32%
Marshall Wace LLPas of 31 Mar 2024951.06k4.50%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024933.36k4.41%
Caligan Partners LPas of 31 Mar 2024858.07k4.06%
Acadian Asset Management LLCas of 31 Mar 2024853.90k4.04%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.